Introduction
Children with congenital heart disease (CHD) face five times greater risk for neurodevelopmental impairments compared to their healthy peers [Reference Jerrell, Shuler, Tripathi, Black and Park1], yet underlying causes remain unknown [Reference Mussatto, Hoffmann and Hoffman2]. Potential physiological factors include dysregulated cerebrovascular health in children with CHD. We indexed cerebrovascular health with: (1) cerebrovascular autoregulation (CA), the brain’s homeostatic mechanism to regulate its blood flow [Reference Armstead3], (2) regional cerebral oxygenation (rcSO2), and (3) cerebral fractional tissue oxygen extraction (FTOE) [Reference Wolfsberger, Pichler-Stachl and Höller4], which measures the brain’s oxygen consumption. Cerebral blood flow (CBF) relying on systemic blood pressure due to CA impairment may not fulfill oxygen demands, increasing the risk of hypoxic-ischemic injury [Reference Vesoulis and Mathur5]. Furthermore, increased FTOE may signal constant or elevated oxygen consumption with reduced or inadequate delivery. CHD neonates show increased FTOE and impaired CA preoperatively [Reference Votava-Smith, Statile and Taylor6], intraoperatively [Reference Smith, Vu and Kibler7], and immediately postoperatively [Reference Pezzato, Govindan and Bagnasco8], although it remains unclear whether these persist into early infancy.
We developed a novel measure (cerebrovascular stability) that uses repeated measures of changes in rcSO2 after tilting as a proxy for CA. Our method stimulates blood pressure fluctuations via tilting. We previously observed reduced cerebrovascular stability in CHD neonates compared to healthy controls (HC) using these methods [Reference Tran, Votava-Smith and Wood9], as rcSO2 declined in CHD neonates (suggesting impaired CA), but increased in HCs after tilting. Likewise, rcSO2 decreased when moving preterm [Reference Petrova and Mehta10] and healthy neonates in varying positions [Reference Fyfe, Yiallourou, Wong, Odoi, Walker and Horne11], but none have demonstrated differences in cerebrovascular stability and FTOE beyond the neonatal period. Therefore, our study assessed whether our indices for cerebrovascular health persists into the 3-month age. We expanded our dataset from a prior neonatal cohort and added data at the 3-month age [Reference Tran, Votava-Smith and Wood9]. We hypothesized that CHD infants would have poorer indices of cerebrovascular health (i.e., significantly lower rcSO2, reduced cerebrovascular stability, and increased FTOE than HCs at both ages. We compared these indices in single ventricle (SV) versus biventricular (BV) and cyanotic versus acyanotic cardiac defects.
Methods
Participants
Our 2-group (CHD and HCs), observational, and longitudinal cohort study examined indices of cerebrovascular health at neonatal and 3-month ages. We recruited CHD infants consecutively admitted to intensive care units and pregnant mothers from fetal cardiology clinics at Children’s Hospital Los Angeles (CHLA) between June 2018 and July 2023. HC were recruited from AltaMed within CHLA and Los Angeles community clinics. Parents provided written informed consent for all participating infants. All procedures adhered to ethical standards of the relevant national guidelines on human experimentation (Good Clinical Practice) and Helsinki Declaration of 1975, and was approved by the Institutional Review Boards of CHLA and AltaMed.
Inclusion criteria: (1) postnatal age of ≤14 days at the neonatal age and (2) gestational age ≥37 weeks at birth. CHD neonates were preoperative or pre-intervention requiring admission to CHLA. HCs had no major prenatal, delivery, or postnatal complications. Exclusion criteria: (1) congenital anomalies other than CHD, (2) major genetic abnormality, (3) intrauterine growth restriction, (4) maternal chorioamnionitis, (5) neurologic abnormalities such as seizures, (6) antibiotics use for a known infection, or (7), hemodynamic instability (dopamine ≥5mcg/kg/min) at the time of assessment. The CHD group had a cardiac intervention before their 3-month visit. We assessed infants within two weeks of birth or two weeks of turning 3-months old. Please refer to the Flow Diagram for sample details by age (Supplemental Fig. 1).
Data collection
We placed an rcSO2 sensor on their forehead and connected to the monitor (INVOS 5100C Somanetics, Troy, MI), and connected a preductal arterial SpO2 sensor on the right hand to the Philips Intellivue MP70. Both monitors connected to a Bernoulli data aggregation system (Cardiopulmonary Corporation, Milford, CT). We swaddled the infants, ensuring a comfortable, calm state, and used a band to secure the head upright during tilts which prevented stress-induced intrathoracic pressure changes that potentially affect blood pressure. The examiner’s left hand supported the infant’s back and spine, while the right preserved head, neck, and chin alignment, ultimately minimizing slouching or abdominal compression.
We acquired data continuously for 2 minutes while the infant was in the supine (0°) posture, then tilted the infant to a sitting (90°) posture. Data acquisition continued for another 2 minutes in the sitting posture. We performed this process for 3 tilt cycles. If the infant became upset during data collection, we pacified the infant and restarted the procedure until 3 cycles were successfully completed.
Measurements
We obtained demographic and clinical data, including medical history, cardiac anatomy and procedures, complications, comorbidities, and current medications from parent report and medical abstraction. Our outcome measures were rcSO2, cerebrovascular stability, and FTOE. Mean values were calculated from the last 2-minutes of the supine posture and the first 2-minutes of the sitting posture across three tilt replicates per participant. rcSO2 and SpO2 were recorded at 5-second intervals, ∼25 values in each posture for each of the 3 tilts, totaling ∼ 150 values obtained per participant at each age. We calculated FTOE for each participant at each 5-second interval using their rcSO2 and SpO2 with the formula: FTOE = ([SpO2-rcSO2]/SpO2).
Statistical analyses
We performed statistical analyses using IBM SPSS Statistics version 27. A G×Power 3.1 analysis indicated a sample size of 46 would detect a large effect size (d = ∼0.6), with α = 0.05 and β = 0.80, when using linear mixed models for repeated measures comparing cerebrovascular stability and FTOE between groups [Reference Tran, Votava-Smith and Wood9,Reference Lakens12].
We examined distributions, correlations, and scatterplots to detect outliers beyond 3 standard deviations. We checked outliers for entry errors and artifacts (e.g., movement), corrected mistakes, and excluded artifact-induced outliers from analyses. We included the few remaining outlier values as possible population representatives. Pearson correlation analyzed: (1) rcSO2 vs. FTOE and (2) rcSO2 vs. SpO2. Chi-square/Fisher’s exact tests and t-tests compared categorical variables and continuous variables between groups, respectively. We examined fit and assumptions for all models.
Hypothesis testing
Separate linear mixed models for repeated measures compared rcSO2, cerebrovascular stability, and FTOE between groups at both ages. Neonatal models included main effects for group and posture, group-by-posture interactions, and covariates of postconceptional age (the sum of gestational age at delivery and postnatal age), ethnicity, sex, and SpO2, with participants as a random factor. The 3-month models removed postconceptional age covariate based on literature suggesting minimal effect on rcSO2 and CBF by this age [Reference Votava-Smith, Statile and Taylor6,Reference Kehrer, Blumenstock, Ehehalt, Goelz, Poets and Schöning13]. The group effect tested our hypothesis that CHD infants would have lower rcSO2 and higher FTOE than HCs. The group-by-posture interaction assessed whether cerebrovascular stability was reduced in CHD infants and if extraction was higher post-tilt.
Sensitivity analyses
We evaluated cerebrovascular stability and rcSO2 consistency by excluding the SpO2 from the models. Additionally, we ran the primary analyses for infants with visits at both ages, to compare the results. Lastly, we assessed the consistency of parameters for cerebrovascular stability when including postconceptional age as a covariate at the 3-month age.
Subgroup effects
Heart defects were classified at each age as SV versus BV and cyanotic (i.e., intracardiac defects that cause right to left shunting) versus acyanotic. Separate linear mixed models for repeated measures assessed whether rcSO2, cerebrovascular stability, and FTOE differed among defects at each age. The models included defect-by-posture interactions, main effects for ventricular type (SV vs. BV) or cyanosis (no vs. yes) and posture, and covariates of postconceptional age (only included in the neonatal model), sex, and SpO2.
Exploratory analyses
We determined whether posture effects observed for rcSO2, and cerebrovascular stability extended to SpO2 by running the same models as listed in the hypothesis testing at both ages, but used SpO2 as the dependent variable. P-values were reported at a 2-sided significance level of 0.05, without multiple comparison adjustments for post hoc and exploratory analyses.
Results
Descriptive statistics
The flow diagram (Supplemental Fig. 1) depicts the final sample at the neonatal (101 infants: 52 CHD and 49 HC) and 3-month age (108 infants: 45 CHD and 63 HC). 30 CHD infants and 42 HC had data at both ages for the sensitivity analyses. Table 1 displays demographic characteristics of both groups. The CHD group had a variety of heart defects (Table 2). Figures 1 and 2 show a time series of all rcSO2 and FTOE.

Figure 1. We display a time series of all rcSO2 values averaged at each time point across all infants in each group at the neonatal (a–b) and the 3-month ages (c–d). (a) Healthy controls (Neonatal age). (b) Congenital heart disease (Neonatal age). (c) Healthy controls (3-month age). (d) Congenital heart disease (3-month age).

Figure 2. We display a time series of all FTOE values averaged at each time point across all infants in each group at the neonatal (a–b) and the 3-month ages (c–d) for both groups. (a) Healthy controls (Neonatal age). (b) Congenital heart disease (Neonatal age). (c) Healthy controls (3–month age). (d) Congenital heart disease (3-month age).
Table 1. Demographics and physiologic measures of the CHD and HC infants at the neonatal and 3-month ages

Group comparisons employed either two-sample t-tests or chi-square tests. P-values were 2-sided. CHD = congenital heart disease; FTOE = fractional tissue oxygen extraction; HC = healthy controls; rcSO2 = cerebrovascular oxygenation; SpO2 = preductal systemic oxygenation; *p < 0.05, **p ≤ 0.001.
Table 2. Types of cardiac defects in the CHD group at both ages

AVSD = atrioventricular septal defect; CHD = congenital heart disease; D-TGA = Dextro Transposition of the Great Arteries; DORV = Double outlet right ventricle; L-TGA = Levo Transposition of the Great Arteries; VSD = ventricular septal defect.
a = Cardiac defects with cyanosis at this timepoint.
b = One subject in this group was cyanotic at this age due to pulmonary artery banding.
Correlations of rcSO2, FTOE, and SpO2
rcSO2 and FTOE demonstrated a strong inverse correlation across all participants at both ages (neonatal: r = –0.92 p < 0.001; 3-month: r = –0.88, p < 0.001). CHD: We observed a significant inverse correlation between rcSO2 and FTOE at both ages (neonatal: r = –0.85, p < 0.001; 3-month: r = –0.80, p < 0.001). HC: Similarly, rcSO2 and FTOE had a significant inverse correlation between at both ages (neonatal: r = –0.98, p < 0.001; 3-month: r = –0.99, p < 0.001).
rcSO2 and SpO2 were moderately correlated in the sample at both ages (neonatal: r = 0.64, p < 0.001; 3-month: r = 0.53, p < 0.001). CHD: We found similar results at the neonatal age (r = 0.64, p < 0.001). However, this correlation became weaker at 3-months (r = 0.38, p = 0.010). HC: We found an inverse correlation, but not significant, at both ages (neonatal: r = -0.201, p = 0.17; 3-month: r = −0.12, p = 0.346).
rcSO2 and FTOE between groups
CHD versus HC
The main effect of group on rcSO2 was significant at both ages (Type III Sums of Squares [T3SS]; neonatal: F = 61.33, df = 92.13, p < 0.001; 3-month: F = 46.40, df = 105.20, p < 0.001). CHD infants had lower rcSO2 (neonatal: ∼13%; 3-month: ∼11%) than HCs in both postures (Figure 3), and disproportionate to the levels predicted by their lower SpO2.

Figure 3. Tilt effects for rcSO2 (a–b) and FTOE (c–d) between the groups at the neonatal and 3-month ages. These figures demonstrate the direction of effects for cerebrovascular stability and FTOE response in each group at both the neonatal and 3-month ages. rcSO2 and FTOE values are the least square marginal means estimated from linear mixed models for repeated measures that tested the main effects for group and posture and the group-by-posture interaction on rcSO2 and FTOE when covarying for postconceptional age (only at the neonatal age), sex, ethnicity, and SpO2. Group and group-by-posture interaction effects were significant at both ages for rcSO2 and FTOE (p’s<0.001). rcSO2 declined from the supine to sitting posture in both groups, but the magnitude of the decline was greater in the CHD group. The red lines for rcSO2 represent the HC response after the tilt (neonatal: β = –1.27, 95% CI [–1.43, –1.11] and the 3-month: β = –0.63, 95% CI [–0.80, –0.46]) (a–b). The blue lines represent the CHD response after the tilt (neonatal: β = –1.67, 95% CI [–1.83, –1.51] and the 3-month: β = –1.5435, 95% CI [–1.74, –1.33]) (a–b). FTOE values increased from the sitting to supine posture in both groups, but the magnitude of the increase was greater in the CHD group. The red lines for FTOE represent the HC response after the tilt (neonatal: β = 0.013, 95% CI [0.011, 0.014] and the 3-month: β = 0.007, 95% CI [0.004, 0.009]) (c–d). The blue lines represent the CHD response after the tilt (neonatal: β = 0.019, 95% CI [0.017, 0.021] and the 3-month: β = 0.015, 95% CI: [0.01, 0.02]) (c–d). Error bars represent standard error. CHD = congenital heart disease; FTOE = fractional tissue oxygen extraction; rcSO2 = regional cerebral oxygenation; SpO2 = preductal systemic oxygenation. **p ≤ 0.001.
Likewise, the main effect of group on FTOE was significant at both ages (T3SS; neonatal: F = 56.53, df = 92.10, p < 0.001; 3-month: F = 18.48, df = 63.99, p < 0.001). CHD infants had higher FTOE (neonatal: ∼0.14 points; 3-month: ∼0.09 points) compared to HCs in both postures (Figure 3).
Sensitivity analyses
Results were consistent when removing SpO2 as a covariate (T3SS; neonatal: F = 59.89, df = 94.01, p < 0.001; 3-month: F = 61.18; df = 103.96, p < 0.001). Additionally, the infants with data at both ages yielded similar findings for main effect of group (T3SS; neonatal: F = 63.72, df = 90.04, p < 0.001; 3-month: F = 45.32; df = 105.47, p < 0.001). Lastly, the main effect of group was consistent when including postconceptional age as a covariate at 3-months (T3SS; 3-month: F = 35.02; df = 70.03, p < 0.001).
Heart defect subgroups
SV versus BV CHD
The main effect of rcSO2 was not significant at the neonatal age, but was at 3-months (T3SS; neonatal: F = 3.44, df = 44.85, p = 0.07; 3-month: F = 3.91, df = 41.86, p = 0.049). Similarly, the main effect of ventricular type on FTOE trended towards significance at the neonatal age, but was significant at 3-months (T3SS; neonatal: F = 3.74, df = 44.83, p = 0.06; 3-month: F = 4.43, df = 42.08, p = 0.04).
Cyanotic versus acyanotic CHD
The main effects of cyanosis on rcSO2 and FTOE, was significant at the neonatal age (T3SS; rcSO 2 : F = 15.10, df = 45.17, p < 0.001; FTOE: F = 15.47, df = 45.16, p < 0.001). However, this was not significant at 3-months (rcSO 2 : F = 1.29, df = 42.01, p = 0.26; FTOE: F = 2.16, df = 42.22, p = 0.15).
Cerebrovascular stability and FTOE response to tilt between groups
CHD vs HC
We observed a significant group-by-posture interaction on cerebrovascular stability at both ages (neonatal: β = –0.39, 95% CI: [–0.63, –0.17], p < 0.001; 3-month: β = –0.90; 95% CI: [–1.17, –0.64], p < 0.001) indicating lower rcSO2 in CHD versus HCs after tilting (Supplemental Table 1). CHD infants showed a greater decline in rcSO2 at both ages (neonatal: β = –1.67, 95% CI: [–1.83, –1.51], p < 0.001; 3-month: β = –1.54, 95% CI: [–1.74, –1.33], p < 0.001), than the HC (neonatal: β = –1.27, 95% CI: [–1.43, –1.11], p < 0.001; 3-month: β = –0.63, 95% CI: [–0.80, –0.46], p < 0.001) (Figure 3).
We also observed a significant group-by-posture interaction on FTOE at both ages (neonatal: β = 0.006, 95% CI: [0.003, 0.009], p < 0.001; 3-month: β = 0.008; 95% CI: [0.004, 0.012], p < 0.001), indicating higher FTOE in CHD compared to HC after tilting (Supplemental Table 2). CHD group had increased FTOE (neonatal: β = 0.019, 95% CI [0.017, 0.021], p < 0.001; 3-month: β = 0.015, 95% CI: [0.012, 0.018], p < 0.001) than the HCs (neonatal: β = 0.013, 95% CI: [0.011, 0.014], p < 0.001; 3-month: β = 0.007, 95% CI: [0.004, 0.009], p < 0.001) at both ages (Figure 3).
Sensitivity analyses
Estimates for the group-by-posture interaction on rcSO2 remained consistent when excluding SpO2 from the models (neonatal: β = –0.10, 95% CI: [–0.08, –0.13] p < 0.001; 3-month: β = –0.21, 95% CI: [–0.19, –0.24] p < 0.001). Moreover, the mixed-effects models using only infants with data at both ages, revealed comparable results (neonatal: β = –0.79, 95% CI: [–1.07, –0.51], p < 0.001; 3-month: β = –0.75; 95% CI: [–1.09, –0.41], p < 0.001).
Heart defect subgroups
SV versus BV CHD
The estimated ventricle type-by-posture interaction on rcSO2 was significant at both ages (neonatal: β = –0.78, 95% CI: [0.42, 1.14], p < 0.001; 3-month: β = –0.77; 95% CI: [–1.24, –0.29], p = 0.001) (Supplemental Table 3). Both SV and BV CHD had declines in rcSO2 after tilts at both ages (Figure 4). However, neonates with BV CHD (β = –1.94, 95% CI: [–2.15, –1.74], p < 0.001) had a larger decline in rcSO2 after tilting compared with the SV group (β = –1.17, 95% CI [–1.46, –0.87], p < 0.001). Conversely, at the 3-month age, the SV (β = –2.43, 95% CI: [–2.76, –2.10], p < 0.001) exhibited a larger drop in rcSO2 compared to the BV CHD (β = –1.19, 95% CI: [–1.51, –0.88], p < 0.001). The interaction effect on FTOE was also significant at both ages (neonatal: β = –0.009, 95% CI: [–0.013, –0.005], p = 0.001; 3-month: β = 0.012, 95% CI: [0.006, 0.017], p < 0.001) (Supplemental Table 4). Both SV and BV infants experienced an increase in FTOE after tilting at both ages (Figure 4). This increase was greater in BV infants at the neonatal age (BV: β = 0.022, 95% CI: [–0.024, –0.020], p = 0.001; SV: β = 0.013, 95% CI: [–0.016, –0.009], p = 0.002). However, it did not persist at 3-months, where SV infants had increased FTOE (BV: β = 0.011, 95% CI: [–0.015, –0.007], p = 0.002; SV: β = 0.023, 95% CI: [–0.027, –0.018], p = 0.002).

Figure 4. Tilt effects for rcSO2 (a–b) and FTOE (c–d) between the biventricular and single ventricle CHD at the neonatal and 3-month ages. These figures demonstrate the direction of effects for the cerebrovascular stability and FTOE between the biventricular (BV) versus single ventricle (SV) CHD groups at both the neonatal and 3-month ages. rcSO2 and FTOE values are the least square marginal means estimated from linear mixed models for repeated measures that tested the ventricle type-by-posture interaction on rcSO2 and FTOE when covarying for postconceptional age (only at the neonatal age), sex, ethnicity, and SpO2. Ventricle type-by-posture interaction effects were significant at both ages for rcSO2 and FTOE (p’s<0.001). rcSO2 declined from the supine to sitting posture in both groups, but the magnitude of the decline was greater in the BV group at the neonatal age. Conversely, the SV group exhibited a greater decline in rcSO2 compared to the BV infants at the 3-month age. The red lines for rcSO2 represent the BV CHD response after the tilt (neonatal: β = –1.94, 95% CI [–2.15, –1.74] and the 3-month: β = –1.19, 95% CI [–1.51, –0.88]). The blue lines represent the SV CHD response after the tilt (neonatal: β = –1.17, 95% CI [–1.46, –0.87] and the 3-month: β = –2.43, 95% CI [–2.76, –2.10]) (a–b). FTOE increased from the sitting to supine posture in both groups, but the magnitude of the increase was greater in the BV group at the neonatal age and in the SV group at the 3-month age (a–b). For FTOE, the red lines represent the BV CHD response after the tilt (neonatal: β = 0.022, 95% CI [–0.024, –0.020] and the 3-month: β = 0.011, 95% CI [–0.015, –0.007]) (c–d). The blue lines represent the SV CHD response after the tilt (neonatal: β = 0.013, 95% CI [–0.016, –0.009] and the 3-month: β = 0.023, 95% CI [–0.027, –0.018]) (c–d). The error bars represent standard error. CHD = congenital heart disease; FTOE = fractional tissue oxygen extraction; rcSO2 = regional cerebral oxygenation; SpO2 = preductal systemic oxygenation. **p ≤ 0.001.
Cyanotic versus acyanotic CHD
The cyanosis-by-posture interaction on rcSO2 was not significant at either age (neonatal: β = 0.07, 95% CI: [–0.44, 0.30], p = 0.72; 3-month: β = –0.34; 95% CI: [–0.14, 0.82], p = 0.16) (Supplemental Table 5). However, the patterns of the decline differed, cyanotic infants had a greater decline at the neonatal age and acyanotic infants exhibited a greater decline at the 3-month age (Figure 5). Similarly, the cyanosis-by-posture interaction effect on FTOE was not significant at both ages (neonatal: β = 0.003, 95% CI: [–0.001, 0.007], p = 0.121; 3-month: β = 0.001; 95% CI: [–0.004, 0.007], p = 0.62 (Supplemental Table 6). Both groups increased FTOE after tilts at both ages (Figure 5). The magnitude of increase in FTOE was greater in cyanotic CHD at the neonatal age (acyanotic: β = 0.017, 95% CI: [0.01 0.02], p < 0.001; cyanotic: β = 0.02, 95% CI: [0.018, 0.022], p < 0.001) and at the 3-month age (acyanotic: β = 0.02, 95% CI: [0.011, 0.020], p = 0.002; cyanotic: β = 0.017, 95% CI: [0.013, 0.021], p = 0.002).

Figure 5. Tilt effects for rcSO2 (a–b) and FTOE (c–d) between the cyanotic and acyanotic CHD at the neonatal and 3-month ages. These figures demonstrate the direction of effects for the cerebrovascular stability between the cyanotic versus acyanotic CHD groups at the neonatal and 3-month age. rcSO2 and FTOE values are the least square marginal means estimated from linear mixed models for repeated measures that tested the cyanosis-by-posture interaction on rcSO2 and FTOE when covarying for postconceptional age (only at the neonatal age), sex, ethnicity, and SpO2. Both cyanotic and acyanotic infants with CHD experienced a decline in rcSO2 during postural changes from supine to sitting at both ages, although cyanotic infants showed a greater decline at the neonatal age and acyanotic infants exhibited a greater decline at the 3-month age. The red lines for rcSO2 represent the acyanotic CHD response after the tilt (neonatal: β = –1.63, 95% CI [–1.94, –1.31] and the 3-month: β = –1.75, 95% CI [–2.11, –1.39]) (a–b). The blue lines represent the cyanotic CHD response after the tilt (neonatal: β = –1.70, 95% CI [–1.89, –1.49] and the 3-month: β = –1.41, 95% CI [–1.72, –1.09]) (a–b). FTOE increased from the sitting to supine posture in both groups, but the magnitude of the increase was greater in the cyanotic group at both ages. The red lines for FTOE represent the acyanotic CHD response after the tilt (neonatal: β = 0.017, 95% CI [0.013, 0.020] and the 3-month: β = 0.016, 95% CI [0.011, 0.020]) (c–d). The blue lines represent the cyanotic CHD response after the tilt (neonatal: β = 0.020, 95% CI [0.018, 0.022] and the 3-month: β = 0.017, 95% CI [–0.013, –0.021]) (c–d). Error bars represent standard error. CHD = congenital heart disease; FTOE = fractional tissue oxygen extraction; rcSO2 = regional cerebral oxygenation; SpO2 = preductal systemic oxygenation.
Exploratory analysis: systemic hypoxemia
We found significant main effects for group at both ages (T3SS; neonatal: F = 29.44, df = 92.94, p < 0.001; 3-month: F = 55.50, df = 104, p < 0.001) and for the group-by-posture interaction at the neonatal (β = –0.19, 95% CI: [–0.35, –0.04], p = 0.01), but not at the 3-month age (β = 0.12, 95% CI: [–0.05, 0.30], p = 0.18). Thus, group differences in the effects of posture on rcSO2 at 3-months were specific to the brain and did not mirror the effects of SpO2. The CHD group revealed significant effects of posture on SpO2 at 3-months (neonatal: β = –0.13, 95% CI: [–0.01, 0.27], p = 0.07; 3-month: β = 0.18, 95% CI: [0.34, 0.03], p = 0.01).
Discussion
Cerebral oxygenation and FTOE differences between groups
CHD versus HC
rcSO2 values (∼60%) were 11–13 points lower, on average, in the CHD group at both ages compared to HC, consistent with previous findings [Reference Peyvandi, Xu and Wang14]. This reduction likely results from oxygenated and deoxygenated blood mixing due to heart defects. Our CHD group exhibited a moderate to weak correlation between rcSO2 and SpO2, suggesting that lower SpO2 may contribute to rcSO2 reductions, potentially failing to meet cerebral metabolic needs (particularly during times of increased demand or stress) and increasing the risk of hypoxic injury [Reference Tran, Votava-Smith and Wood9,Reference Peyvandi, Xu and Wang14]. In our cohort, this effect persisted to the 3-month age.
rcSO2 and FTOE were inversely correlated in both groups at both ages. This correlation was stronger in HC, indicating their greater regulation between rcSO2 and FTOE. Larger rcSO2 reductions in CHD infants likely contribute to their higher FTOE, a pattern also seen in preterm infants with intraventricular hemorrhage compared to those without [Reference Matyas, Iancu, Hasmasanu, Man and Zaharie15].
FTOE was 0.09–0.14 points higher in CHD infants than HCs at both ages, consistent with findings showing higher preoperative FTOE and lower CBF in SV CHD neonates compared to HCs [Reference Dehaes, Cheng and Buckley16]. We theorize that increased FTOE reflects decreased oxygen delivery due to inadequate oxygen supply from heart defects, as maximal extraction is unexpected as a compensatory mechanism during early infancy. Research on FTOE beyond the immediate postoperative period remains limited in CHD infants, however, our neonatal findings align with previous findings demonstrating increased FTOE in this population [Reference Merkel, Brady, Votava-Smith and Tran17].
Both groups exhibited an expected developmental decline in rcSO2 and increased FTOE across ages. These changes resulted in group differences in oxygenation and extraction that were consistent in magnitude across both ages, which suggests persistent cerebral hypoxia in CHD infants during the first 3-months of life (despite 87% having undergone corrective or palliative surgery). Specifically, rcSO2 in CHD infants dropped from 67% neonatally to 51% at 3-months, while FTOE increased from 0.271 to 0.422. Average neonatal FTOE (0.271) is lower than in healthy adults as reported in studies (0.328 to 0.380) [Reference Cho, Lee, An, Goyal, Su and Wang18,Reference Cho, Ma, Spincemaille, Pike and Wang19]. The age-related increase in FTOE likely reflects the natural decline in fetal hemoglobin, which has higher oxygen affinity than adult hemoglobin, bringing values closer to those of a healthy child or adult [Reference Jia, Ghi, Pereira, Gracia Perez-Bonfils and Chandraharan20].
However, the mechanisms driving persistent cerebral hypoxia post-surgery, particularly in BV CHD, remain unclear, as only 21% of the BV group remained cyanotic at the 3-month age. One likely driver is the transition from fetal to adult hemoglobin, beginning in late gestation and typically complete by 3-months or after blood transfusions [Reference Sankaran and Orkin21]. A previous study on preterm infants found that lower hemoglobin correlated with decreased rcSO2 and increased FTOE due to reduced oxygen transport [Reference van Hoften, Verhagen, Keating, ter Horst and Bos22]. Adult hemoglobin facilitates oxygen unloading, lowering cerebral oxygenation [Reference Gavulic, Dougherty and Li23]. Thus, rcSO2 reductions in healthy infants may reflect normal physiological adaptation via lower CBF, however, CHD infants had reduced cerebral oxygenation and compromised cerebral hemodynamics [Reference Votava-Smith, Statile and Taylor6], suggesting their lower rcSO2 may indicate physiological stress. Physiologic anemia also accompanies this hemoglobin transition, with hematocrit levels lowest around 6 weeks. rcSO2 often tracks hematocrit levels [Reference Svedung Wettervik, Engquist and Hånell24], which typically increases and stabilizes by 3-months of age [Reference Seo and Oh25]. Cyanotic CHD infants might demonstrate higher hematocrits than acyanotic, but this modest compensatory polycythemia often manifests later in life. Our study did not collect hemoglobin nor hematocrit, limiting insight into the relationship between hemoglobin, rcSO2, and FTOE. Notably, our primary outcomes were preserved when controlling for oxygen saturation, a known driver for hematocrit differences. Future studies should include hemoglobin measurements to further explore the mechanisms of persistent cerebral hypoxia in CHD.
Heart defect subgroups
SV versus BV CHD
SV rcSO2 levels were 4.96% to 6.17% lower than BV at both ages, with significant differences only at the 3-month age, suggesting a progressive hemodynamic divergence. SV physiology relies on one ventricle to supply both systemic and pulmonary blood flow, causing volume overload and arterial desaturation due to mixing of oxygenated and deoxygenated blood [Reference Hauck, Porta, Lestrud and Berger26]. Significant rcSO2 reductions at 3-months suggests that cumulative effects may further reduce rcSO2 in SV compared to BV CHD. Limited pediatric studies compare rcSO2 between ventricle type defects, but one adult study found persistently reduced rcSO2 and higher hemoglobin in SV versus BV CHD [Reference Dib, Iserin and Varnous27]. Other reports demonstrated preoperative cerebral hypoperfusion and postoperative rcSO2 declines in CHD infants with SV defects [Reference Pezzato, Govindan and Bagnasco8], implying that SV physiology imposes a lasting, greater hemodynamic burden, reducing rcSO2 into adulthood.
FTOE in SV CHD was 0.054–0.068 points higher than BV at both ages, with significance only at 3-months. This aligns with another study finding lower rcSO2 and higher FTOE in SV versus BV CHD infants before and after blood transfusions [Reference Neunhoeffer, Hofbeck, Schlensak, Schuhmann and Michel28]. Likewise, a report found increased FTOE in older infants with SV versus BV CHD pre- and postoperatively [Reference Buckley, Lynch and Goff29]. These findings corroborate our results of lower rcSO2 in BV neonates, indicating that increased FTOE compensates for lower rcSO2 in BV neonates, but this shifts by 3-months, likely due to growing hemodynamic strains from SV defects and incomplete cerebral recovery or adaptation after surgery [Reference Dehaes, Cheng and Buckley16].
Cyanotic versus acyanotic CHD
Neonates with cyanotic defects had ∼ 10% lower rcSO2 than acyanotic, with differences persisting at 3-months but attenuating to ∼ 3% lower, perhaps due to age and intervening surgery. We anticipated this finding because cerebral oxygenation is a function of systemic saturation, which naturally results in lower rcSO2 in cyanotic infants. Thus, observed rcSO2 differences between SV and BV groups are unlikely due to cyanosis alone.
Studies comparing rcSO2 between cyanotic heart lesions remains scarce. One contrasted our neonatal findings, found no significant differences in rcSO2 between lesion groups, possibly due to a smaller sample size [Reference Fister, Robek, Paro-Panjan, Mazić and Lenasi30]. However, prior studies indicated lower CBF via brain MRI in the thalamus, basal ganglia, and occipital white matter in cyanotic neonates, which supports a mechanism for lower brain oxygenation [Reference Sun, Liu, Yu and Zhong31]. Results at 3-months did not reach significance, however, findings suggests cyanotic CHD infants’ potential reliance on FTOE to meet cerebral metabolic demands. Variability of cyanotic heart defects and surgical effects may contribute to these observations. Cyanotic defects have both increased and decreased pulmonary blood flow [Reference Waldman and Wernly32,Reference Alahmadi, Sharma and Bishop33], resulting in differing levels of cerebral oxygen delivery at birth. Early clinical interventions may help stabilize rcSO2 and minimize the effects of these variations in oxygen delivery by 3-months.
Cyanotic CHD also trended towards increased FTOE than acyanotic at both ages. Our findings aligned with studies in other populations showing increased FTOE as oxygen saturation (e.g., preterm infants [Reference Solaz-García, Sánchez-Illana and Lara-Cantón34] and adults) [Reference Yin, Shu, Qin, Shan, Gao and Lu35]. Likewise, another study revealed that acyanotic CHD infants exhibited significantly higher FTOE compared to cyanotic [Reference Kussman, Laussen, Benni, McGowan and McElhinney36]. Differences in findings may result from differing measurement techniques, like the FORE-SIGHT monitor, and sample size variations.
Cerebrovascular stability differences and FTOE response to tilt between groups
CHD versus HC
Our findings suggest reduced cerebrovascular stability in CHD infants preoperatively, persisting to 3-months post-surgery. rcSO2 declined while FTOE increased significantly after tilting to a seated position at both ages compared to healthy infants.
The reduced cerebrovascular stability in CHD infants align with our prior work, which showed a significant decline in rcSO2 after tilting in CHD neonates [Reference Tran, Votava-Smith and Wood9]. Reports measuring cerebrovascular stability in CHD infants are limited, however, existing studies in preterm infants have yielded inconsistent rcSO2 responses to position changes [Reference Tran, Tran, Elgabalawy, Lopez and Kysh37]. Some reported significant declines after tilting [Reference Barsan Kaya, Aydemir and Tekin38,Reference Li, Ye and Li39], whereas others found no differences [Reference Wu, Lien, Seri and Noori40,Reference Spengler, Loewe and Krause41], possibly due to variations in preterm study populations [Reference Wu, Lien, Seri and Noori40,Reference Spengler, Loewe and Krause41], tilt angles employed, rest durations between position changes [Reference Ravarian, Nariman and Noori42], or time durations within each posture [Reference Ravarian, Nariman and Noori42,Reference Demirel, Oguz, Celik, Erdeve and Dilmen43]. We observed significant rcSO2 decreases after tilting between the CHD and HC groups (0.5% at the neonatal age and ∼ 0.9% at 3-months), however, their clinical relevance remains uncertain when considered independently. Nevertheless, the persistence to 3-months suggests continued physiological differences between the two groups, despite 42% of the CHD cohort having undergone corrective cardiac surgery prior to that timepoint. These findings suggest enduring cerebrovascular vulnerabilities in high-risk infants, like those with CHD.
Perfusion studies via MRI or cranial ultrasound, for example, have reported reduced oxygen delivery [Reference Kelly, Makropoulos and Cordero-Grande44], and reduced CBF [Reference Cheatham, Chisolm and O’Brien45] in preoperative CHD infants compared with HC. Similarly, a postmortem study of brains of children with CHD showed diffuse gliosis, suggesting chronic cerebral hypoperfusion may persist from infancy into adulthood [Reference Alturkustani and Szymanski46]. These studies, despite using different methodologies from ours, support the changes in CBF and oxygenation in CHD infants and provide insight into the mechanism for reduced cerebrovascular stability.
Likewise, increased FTOE after tilting in the CHD group align with our previous work in a smaller CHD sample [Reference Merkel, Brady, Votava-Smith and Tran17]. The magnitude of FTOE increase after tilting was also greater at both ages for both groups, suggesting higher metabolic needs and difficulties sustaining sufficient cerebral perfusion during activity [Reference Tataranno, Alderliesten and de Vries47]. In previous studies, CHD infants exhibited up to 35% greater total energy expenditure compared to healthy age-matched controls [Reference Mills, Kim and Fogg48]. This increased oxygen consumption [Reference Balegar, Low and Nanan49], in addition to impaired CA, can overwhelm the infant’s ability to sustain sufficient cerebral perfusion [Reference ter Horst, Verhagen, Keating and Bos50], leading to increased FTOE as the body attempts to meet the elevated metabolic demands [Reference Merkel, Brady, Votava-Smith and Tran17]. This aligns with another study that found associations between increased FTOE and impaired CA in CHD neonates [Reference Votava-Smith, Statile and Taylor6]. CA depends on the cerebral blood vessels’ ability to dilate and constrict based on the changes in perfusion pressure, and in the setting of maximal FTOE, therefore may not be ability to further vasodilate and allow for autoregulation [Reference Derridj, Guedj and Calderon51].
Heart defect subgroups
SV versus BV CHD
We observed significantly reduced cerebrovascular stability for BV at the neonatal age and for SV defects at 3-months. This contrasted our previous study, where rcSO2 did not differ by ventricle type in CHD neonates [Reference Tran, Votava-Smith and Wood9]. Differences in findings may result from our larger sample size, which included 52 CHD neonates compared to 28, previously. The pattern reversed at the 3-months, with reduced cerebrovascular stability and increased FTOE in SV relative to BV CHD (full cardiac repair in 79% prior to 3-months). SV defects are more severe, so poorer cerebrovascular response were expected. Reduced cerebrovascular stability in BV CHD cannot be explained by oxygen saturation (50% of BV neonates were cyanotic and 100% of SV were cyanotic) nor by differences in cardiac output at the neonatal age. At 3-months, most of the BV defects had completely repaired heart lesions compared to the SV whose defects were palliated. Our findings suggest that reparative surgery may have a beneficial effect toward cerebrovascular stability.
The FTOE response demonstrated similar findings, where BV defects had increased FTOE after tilting compared to SV at the neonatal age, while SV defects exhibited a greater increase at the 3-month age. Studies on FTOE during postural changes in SV CHD infants remain limited, however, one report demonstrated increased FTOE in neonates with SV CHD during an active state compared to a sedated state postoperatively [Reference Dehaes, Cheng and Buckley16]. Studies in preterm infants further support our findings, revealing similar increases in FTOE after changes in positions [Reference Solaz-García, Sánchez-Illana and Lara-Cantón34]. Thus, findings suggest that periods of activity, such as during a postural tilt, may increase FTOE to satisfy increased metabolic demands. Again, our 3-month findings indicate that repairing the defect may benefit this response. These findings also suggest the presence of an underlying abnormality distinct from SpO2 alone. Infants with BV hearts may have a greater capacity to augment cardiac output or extract oxygen more effectively during periods of metabolic demand, which would explain the observed shift at the 3-month age.
Cyanotic versus acyanotic CHD
Cyanotic CHD did not exhibit reduced cerebrovascular stability compared to acyanotic CHD at either age. This suggests that SpO2 from intracardiac mixing does not alone account for the abnormalities we observed in our CHD cohort. At the neonatal age, cyanotic defects had significant increases in FTOE after tilting, which contrasted the ventricle type results. We expected reduced cerebrovascular stability in cyanotic CHD, as these infants typically have poorer outcomes. Instead, we observed preserved cerebrovascular stability in cyanotic neonates despite significant increases in FTOE. The explanation remains unclear, and a gap in the literature exists for this topic. However, these results aligned with our prior study showing cerebrovascular stability in neonatal cyanotic CHD [Reference Tran, Votava-Smith and Wood9]. One study suggested that oxygen supply and consumption influences FTOE, as increased FTOE may result from decreased CBF [Reference Verhagen, Ter Horst, Keating, Martijn, Van Braeckel and Bos52], which could explain the increases in FTOE in cyanotic infants compared to acyanotic infants after tilting at the neonatal age. We have not found literature on the relationship between FTOE and tilts in cyanotic CHD infants. However, reports in preterm populations show increased FTOE with reductions in rcSO2 during position changes [Reference Solaz-García, Sánchez-Illana and Lara-Cantón34]. Thus, acutely ill infants experience difficulty maintaining adequate rcSO2, leading to increased FTOE, as the body attempts to meet heightened metabolic demands.
Probable consequences of poorer cerebrovascular health
Cerebral hypoxia, reduced cerebrovascular stability, and increased FTOE implies that CHD infants may experience inadequate cerebral perfusion, especially during periods of physiological stress. Lower rcSO2 may therefore contribute to the poorer long-term developmental outcomes in CHD infants compared to HCs, even after surgical repair of their heart defects [Reference Gaynor, Stopp and Wypij53]. CHD newborns have significant associations of reduced oxygen delivery with lower cortical gray matter volumes and less gyrification on brain MRIs [Reference Kelly, Makropoulos and Cordero-Grande44], potentially due to chronic hypoperfusion. Other findings showed that fluctuations in CBF during the intra- and postoperative periods associated with brain injury and lower neurodevelopmental scores at 1-year old in CHD infants [Reference Bell, Hintz and Hansen54,Reference Locke and Kanekar55]. Increased FTOE after tilting may be a compensatory response to meet cerebral metabolic needs in response to the lower rcSO2 post-tilt [Reference Schlatzer, Schwaberger and Bruckner56 –Reference Balegar, Low and Nanan58], potentially worsening CA [Reference Votava-Smith, Statile and Taylor6]. Continuous cerebral hypoperfusion [Reference Alturkustani and Szymanski46], vacillations in flow, and hypoxia likely injure neurons and glial cells. This injury likely contributes to abnormal brain maturity, manifested as reduced gray and white matter and cortical gyrification, and thus neurodevelopmental disabilities (NDDs) [Reference Kelly, Makropoulos and Cordero-Grande44].
Limitations
Our study had several limitations. First, cerebrovascular stability, using changes in rcSO2 as a proxy for CBF, assumed similar cerebral metabolic rates across groups and postures. We minimized metabolic variability by standardizing infant states during data collection. However, cerebrovascular stability has not been definitively validated in literature, with one study with a small sample size showing a moderate, nonsignificant correlation [Reference Merkel, Brady, Votava-Smith and Tran17 ]. Further research comparing cerebrovascular stability to standard CA methods is necessary.
Second, blood transfusions may have confounded results in CHD neonates. Transfusions replace fetal hemoglobin with adult hemoglobin, lowering oxygen affinity, reducing CBF, and increasing FTOE. These factors complicate FTOE interpretation in this population and highlight the need to consider fetal-to-adult hemoglobin ratios in future studies using hemoglobin electrophoresis.
Third, the use of a single modality, NIRS, to assess cerebrovascular stability without supporting laboratory hemoglobin data or echocardiographic measures limits the clinical relevance of our findings. Echocardiographic insights such as ventricular function, residual lesions, or shunting would provide context for interpreting cerebral oxygenation patterns. While this study offers preliminary data, future studies should incorporate multi-modal approaches to validate these findings and determine their clinical relevance. Fourth, varying cardiac output and physiology likely influenced CBF and cerebrovascular stability across time, as we assessed infants both before and after palliative and corrective heart surgeries. Our limited sample size prevented analysis of specific CHD lesions. Thus, we combined data across different lesions to provide a broader understanding of rcSO2 and FTOE trends in CHD infants, recognizing that lesion-specific variability in clinical presentation may impact outcomes. Medical acuity, hospitalization timing, and impending surgery resulted in missed visits. Nevertheless, our sensitivity analyses of those with consecutive measurements found minimal differences. Variability in CHD defect types may also limit the generalizability of our findings.
Conclusions
We found evidence of poorer cerebrovascular health (i.e., sustained cerebral hypoxia, reduced cerebrovascular stability, and increased FTOE) in neonates and 3-month infants with CHD compared to HCs. These abnormalities persisted beyond the neonatal period, even after cardiac interventions, suggesting that sustained disturbances in cerebrovascular health may contribute to brain injury and NDDs in CHD infants. Future studies should assess our measures of cerebrovascular health as predictors of NDDs in children with CHD, as they may serve as biomarkers to identify high-risk infants. We could then evaluate interventions to improve cerebrovascular health and assess their potential to prevent or attenuate NDDs in children with CHD. Our technique to measure cerebrovascular health is noninvasive, low-cost, and easily replicable in various settings (e.g., clinic and home) and diverse pediatric populations (e.g., high-risk and healthy), offering a potentially valuable tool for clinicians to closely monitor infants at an increased risk for poorer cerebrovascular health and neurodevelopmental delays.
Supplementary material
The supplementary material for this article can be found at https://doi.org/10.1017/cts.2025.10106
Acknowledgements
We extend our sincere gratitude to all the families who contributed to this study and are grateful to the teams at the Heart Institute and Fetal Maternal Center of Children’s Hospital Los Angeles for their essential support and contributions.
Author contributions
Nhu N. Tran: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing-original draft, Writing-review & editing; Jodie K. Votava-Smith: Investigation, Validation, Writing-original draft, Writing-review & editing; John C. Wood: Investigation, Supervision, Validation, Visualization, Writing-original draft, Writing-review & editing; Joanne Yip: Data curation, Formal analysis, Writing-original draft, Writing-review & editing; Andrew Pham: Data curation, Writing-original draft, Writing-review & editing; Mary-Lynn Brecht: Methodology, Supervision, Writing-original draft, Writing-review & editing; Panteha Rezvan: Methodology, Writing-original draft, Writing-review & editing; Anthony Colombo: Methodology, Writing-original draft, Writing-review & editing; Philippe Friedlich: Funding acquisition, Writing-original draft, Writing-review & editing; Ken Brady: Investigation, Methodology, Supervision, Writing-original draft, Writing-review & editing; Bradley Peterson: Investigation, Methodology, Supervision, Writing-original draft, Writing-review & editing.
Funding statement
Research grants and support were received from the Teresa and Byron Pollitt Family Foundation; Robert Wood Johnson Foundation; University of California, Los Angeles, Sigma Theta Tau, Gamma Tau Chapter; Children’s Hospital Los Angeles Clinical Services Research Grant; Gerber Foundation Biostatistics and Data Management Core at The Saban Research Institute, Children’s Hospital Los Angeles and by grants UL1TR001855 and UL1TR000130 from the National Center for Advancing Translational Science (NCATS); Southern California Clinical and Translational Science Institute (SC CTSI) (NCATS) through Grant UL1TR0001855; and NINR K23 Grant 1K23NR019121-01A1. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Competing interests
No authors have financial relationships or conflicts of interest relevant to this article to disclose. The authors have declared that no competing interests exist.
Consent statement
We obtained written informed consent from parents of all participating infants. All procedures contributing to this work complied with the ethical standards of the relevant national guidelines on human experimentation (Good Clinical Practice) and Helsinki Declaration of 1975, as revised in 2008, and was approved by the Institutional Review Boards of CHLA and AltaMed.